Background
The expression/activation of HGF/c-MET in different types of lymphoma and its outcome on tumor progression
B cell-derived lymphoma
Diffuse large B cell lymphoma
Primary effusion lymphoma
Burkitt’s lymphoma
Mucosa-associated lymphoid tissue lymphoma
Hodgkin lymphoma
T and NK cell-derived lymphoma
Type of lymphoma | Outcome | Cellular functions, mechanisms, and clinical consequence | References |
---|---|---|---|
B cell-derived | Unfavorable | Enhanced metastasis in vivo | [15] |
DLBCL | Favorable | ▪ Increase survival of patients ▪ c-MET retained the physiologic growth control ▪ c-MET(+) DLBCL was more proliferated and more responsive to therapy ▪ c-MET directly binds to the pro-apoptotic protein FAS | |
Primary intestinal DLBCL | Unfavorable | Reduce survival of patients | [19] |
DLBCL | Unfavorable | ▪ Increase the activities of MEK-MAPK ▪ Increase the activities of PI3K-PKB/AKT and its substrates GSK3 and FOXO3a ▪ Inhibition of fatty acid synthase | |
PEL | Unfavorable | Required for tumor progression in xenograft model | [37] |
BL | Unfavorable | ▪ Protection of cells from apoptosis ▪ Activation of MAPK ▪ Induce drug resistance of tumor cells | |
MALT | Unfavorable | Required for tumor cell proliferation/growth | [41] |
cHL | Favorable | Increase survival of patients | |
cHL | Unfavorable | Increase the relapse | [47] |
ALCL | Unfavorable | Required for tumor progression | [48] |
NKTCL | Unfavorable | Required for tumor cell proliferation | [49] |
TLL | Unfavorable | Required for tumor progression |
Targeting c-MET in lymphoma
Type of lymphoma | c-MET inhibition | Models/methods | References |
---|---|---|---|
DLBCL | PHA-665752 c-Met siRNA | Cell lines in vitro culture | [18] |
PEL | PF-2341066 | Mice xenograft model | [37] |
MALT | PHA-665752 c-MET mAb | Mice xenograft model | [41] |
cML | SU11274 | Cell lines in vitro culture | [42] |
ALCL | PF-2341066 | Mice xenograft model | [48] |
NKTCL | ARQ197 c-MET mAb | Cell lines in vitro culture | [49] |